Accenture Puts Data Science to Work for Pediatric Leukemia Research
NEW YORK; Sept. 23, 2020 – Accenture (NYSE: ACN) today announced that it has built a data and analytics approach to manage and derive insights from pediatric acute myeloid leukemia (AML) genomic data. Working in collaboration with researchers and clinicians from Fred Hutchinson Cancer Research Center (Fred Hutch), and the Target Pediatric AML (TpAML) computational working group, a large-scale research project which supplied the data, this new approach aims to enable pediatric oncology physicians and researchers — specifically those focused on pediatric AML — to better analyze patient clinical trial and genetic data, with the potential to improve precision medicine.
Comments
Post a Comment